Hsbc Holdings PLC Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

Hsbc Holdings PLC purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 9,643 shares of the company’s stock, valued at approximately $686,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Rockefeller Capital Management L.P. raised its holdings in Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after acquiring an additional 172 shares during the period. State of Wisconsin Investment Board boosted its holdings in shares of Tarsus Pharmaceuticals by 1.1% in the fourth quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after acquiring an additional 332 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 0.6% in the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after acquiring an additional 339 shares during the period. Valeo Financial Advisors LLC boosted its stake in Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after purchasing an additional 392 shares during the period. Finally, Creative Planning grew its stake in Tarsus Pharmaceuticals by 3.3% during the third quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after acquiring an additional 393 shares in the last quarter. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Up 1.7%

Tarsus Pharmaceuticals stock opened at $59.54 on Friday. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The stock has a fifty day moving average of $61.23 and a 200 day moving average of $65.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. The stock has a market cap of $2.56 billion, a PE ratio of -52.23 and a beta of 0.50.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million for the quarter, compared to analysts’ expectations of $149.60 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -1.04 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research note on Friday, April 24th. They issued an “outperform” rating and a $98.00 target price for the company. Guggenheim lowered their price target on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $90.50.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the sale, the director directly owned 106,786 shares of the company’s stock, valued at approximately $6,633,546.32. This represents a 10.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total transaction of $615,500.00. Following the sale, the chief executive officer directly owned 847,991 shares of the company’s stock, valued at approximately $52,193,846.05. The trade was a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 39,850 shares of company stock worth $2,452,821. 9.64% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.